drugset / Trial / NCT03005184
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
RandomizedCrossoverQuadruple-blindBasic science
Summary
This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)
Timeline
- Start
- 2017-09
- Primary completion
- 2020-01
- Completion
- 2020-01
Outcome
Outcome not reported
Stopped: “Study is being redesigned and submitted as a new study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enalapril | Other / unclassified | 10 mg | Oral |
| Subject | Icatibant | Peptide | — | Intravenous |
| Subject | Sacubitril-Valsartan | Unknown | 200 mg | Oral |
| Background | Valsartan | Unknown | 80 mg | Oral |